Related Experiment Video

Updated: May 30, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

[Biological therapy in pediatric rheumatology]

A A Baranov, E I Alekseeva, S I Valieva

    Vestnik Rossiiskoi Akademii Meditsinskikh Nauk
    |July 27, 2011
    PubMed

    Insights

    Biological therapies significantly improve outcomes for children with juvenile rheumatoid arthritis. Gene-engineered drugs achieve remission in 70% of patients, enhancing quality of life and long-term prognosis.

    Area of Science:

    • Pediatric Rheumatology
    • Immunology
    • Pharmacology

    Context:

    • Juvenile rheumatoid arthritis (JRA) is a chronic autoimmune disease affecting children.
    • Traditional immunosuppressants have limitations in managing JRA.
    • The Research Centre of Children's Health has extensive experience in treating pediatric JRA.

    Purpose:

    • To present the experience of treating 438 children with JRA using various biologic agents.
    • To evaluate the efficacy and impact of differential biologic therapy compared to classical immunosuppressants.
    • To assess the effect of gene-engineered drugs on disease activity, remission rates, and patient quality of life.

    Summary:

    • The study involved 438 children treated with biologic preparations: infliximab, adalimumab, etanercept, rituximab, and tocilizumab.
    • Differential biologic therapy achieved clinico-laboratory remission in 70% and reduced disease activity in 20% of patients within one year.
    • This approach contrasts with classical immunosuppressants, showing superior outcomes.

    Impact:

    • Biologic therapy significantly improves the quality of life for children with JRA and their families.
    • Gene-engineered drugs promote normal growth and development in pediatric patients.
    • These treatments positively affect the prognosis of JRA, a previously incurable condition.

    Related Concept Videos

    Inflammatory Bowel Disease IV: Pharmacological Management01:29

    Inflammatory Bowel Disease IV: Pharmacological Management

    Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
    Pharmacologic...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    Gene Therapy00:59

    Gene Therapy

    Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...